Hualan Biological Engineering Inc.
002007
Xếp hạng trong cổ phiếu
#4390
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Giá cổ phiếu
$1.92
Vốn hóa thị trường
$3.50B
Thay đổi (1 ngày)
-1.39%
Thay đổi (1 năm)
-19.45%
Quốc gia
CN
Giao dịch Hualan Biological Engineering Inc. (002007)
Danh mục
Healthcare
EPS của Hualan Biological Engineering Inc. (002007)
EPS tính đến 2026 TTM: 0
Theo các báo cáo tài chính mới nhất và giá cổ phiếu của Hualan Biological Engineering Inc., EPS hiện tại của công ty (TTM) là 0. Vào cuối năm 2026, công ty có EPS là 0, bằng với EPS năm 2026 là 0.
Lịch sử EPS của Hualan Biological Engineering Inc. từ 2001 đến 2026
EPS vào cuối mỗi năm
| Năm | EPS | Thay đổi |
|---|---|---|
| 2025 | $0.07 | -9.61% |
| 2024 | $0.08 | -28.15% |
| 2023 | $0.11 | 33.80% |
| 2022 | $0.09 | -23.46% |
| 2021 | $0.11 | -17.99% |
| 2020 | $0.14 | 35.52% |
| 2019 | $0.10 | 9.72% |
| 2018 | $0.09 | 32.37% |
| 2017 | $0.07 | 11.79% |
| 2016 | $0.06 | 25.56% |
| 2015 | $0.05 | 1.86% |
| 2014 | $0.05 | 12.82% |
| 2013 | $0.04 | 57.14% |
| 2012 | $0.03 | -18.02% |
| 2011 | $0.03 | -35.34% |
| 2010 | $0.05 | 3.41% |
| 2009 | $0.05 | 209.32% |
| 2008 | $0.02 | 71.28% |
| 2007 | $0.01 | 62.07% |
| 2006 | $0.01 | 52.63% |
| 2005 | 0.00 | 31.03% |
| 2004 | 0.00 | -21.62% |
| 2003 | 0.00 | 23.33% |
| 2002 | 0.00 | 87.50% |
| 2001 | 0.00 | 0.00% |
EPS cho các công ty hoặc đối thủ cạnh tranh tương tự
| Công ty | EPS | Chênh lệch EPS | Quốc gia |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $13.70 | - |
BE
|
|
| $27.74 | - |
NL
|
